Revolutionizing the treatment of autoimmune diseases by the endogenous generation of disease-specific regulatory T cells (Tregs)
Navacims™
Current approaches to treating autoimmune disease require broad suppression of the immune system to prevent the immune system from attacking a patient’s own tissue (self). In contrast, our Navacim platform generates disease specific regulatory T cells (Tregs) which reverse autoimmune disease by supressing autoimmune attacks on self without impairing normal immune function.
About Parvus
Parvus’ therapeutic platform is based on the discoveries of Pere Santamaria, M.D., Ph.D., Professor in the Department of Microbiology & Infectious Diseases and Julia McFarlane Chair in Diabetes Research at the Cumming School of Medicine at the University of Calgary.
At Parvus, we are developing disease-specific Navacims as treatment for patients who suffer from autoimmune disease.